Bellevue Group Ag Celldex Therapeutics, Inc. Transaction History
Bellevue Group Ag
- $5.02 Billion
- Q4 2024
A detailed history of Bellevue Group Ag transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Bellevue Group Ag holds 3,071,615 shares of CLDX stock, worth $60.1 Million. This represents 1.55% of its overall portfolio holdings.
Number of Shares
3,071,615
Previous 3,071,615
-0.0%
Holding current value
$60.1 Million
Previous $104 Million
25.61%
% of portfolio
1.55%
Previous 1.76%
Shares
7 transactions
Others Institutions Holding CLDX
# of Institutions
198Shares Held
60.6MCall Options Held
960KPut Options Held
675K-
Kynam Capital Management, LP Princeton, NJ5.06MShares$99.1 Million8.11% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$91.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.88MShares$76 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.75MShares$73.5 Million1.82% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.56MShares$69.6 Million0.01% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $915M
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...